Earlier this month, Teva agreed to pick up U.S. and Canadian rights to a pair of biosims from Korea’s Celltrion. But it might not stop with just two.
The generics giant may consider purchasing the Korean drugmaker itself, a Teva spokesman told Korean news source The Investor.
“We will continue to investigate such opportunities as we balance risk and seek complementary skills in our partners,” he said.
It’s not the first time the idea has come up. Back in early 2014, when Celltrion was planning to sell a controlling stake in the company, Teva’s name popped up in deal rumors–along with those of peers AstraZeneca and Roche.
Why all the interest? Celltrion’s biosim plans are beginning to come to fruition. Along with partner Pfizer, it already boasts an FDA-approved copy of Johnson & Johnson blockbuster Remicade waiting for the green light to launch in the U.S.
And there’s more where that came from. It’s working on versions of Roche oncology giants Rituxan and Herceptin, too–and it granted Teva North American rights to those biosims in a $160 million pact sealed in early October.
Teva CEO Erez Vigodman in particular has highlighted biosimilars as a key component of the Israeli drugmaker’s strategy. But the company has already struck out once in the field: In 2013, one-time biosim partner Lonza backed out of the pair’s 2009 agreement after development and marketing costs piled up.
Meanwhile, Vigodman has also been talking up branded buys since Teva wrapped up its $40 billion Allergan generics buyout. Teva will be looking out for “attractive specialty assets, or branded drug assets or pipeline assets” that fit in with the therapeutic areas it’s already tackling, including pain, neurodegenerative disease and respiratory disorders, Vigodman said in August.
By Carly Helfand
Source: Fierce Pharma
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
